Oncodesign and the Laboratory for Neurobiology and Gene Therapy (LNGT) at the KU Leuven entered a research collaboration to evaluate, with Ipsen, Oncodesign’s compounds in multiple pharmacology models for Parkinson’s disease. The deal builds on Oncodesign’s LRRK2 program with advanced Nanocyclix® lead molecules that was partnered with Ipsen in January 2012.
Under the terms of the agreement, Oncodesign and LNGT will closely collaborate to advance Oncodesign’s Parkinson’s disease program toward clinical development. LNGT will receive full financial support from Oncodesign for these activities.
In January, Ipsen and Oncodesign partnered for the development of new therapeutic agents against LRKK2 involved in Parkinson’s disease, with focus in neurology and movement disorders. The partnership was founded on LLRK2 inhibitors originating from Oncodesign’s Nanocyclix medicinal chemistry technology for developing kinase inhibitor leads. Ipsen retained two options to exclusively license Oncodesign’s LRRK2 inhibitor program for worldwide development and commercialization, on the achievement of clinical proof-of-concept.
“Our partnership with Ipsen on the discovery of novel therapeutic agents in Parkinson’s disease has advanced to a stage where we can use further in depth expertise and advanced pharmacology models to position our leads,” said Jan Hoflack, Ph.D., CSO and head of Oncodesign’s discovery activities.
